| ID Source | ID |
|---|---|
| PubMed CID | 5123423 |
| CHEMBL ID | 1509437 |
| CHEBI ID | 116098 |
| Synonym |
|---|
| smr000219764 |
| MLS000589171 |
| (2-benzyloxy-phenyl)-(2-methoxy-phenylamino)-acetonitrile |
| AJ-292/42152724 |
| [2-(benzyloxy)phenyl](2-methoxyanilino)acetonitrile |
| CHEBI:116098 |
| AKOS005481482 |
| HMS2539M04 |
| 2-(2-methoxyanilino)-2-(2-phenylmethoxyphenyl)acetonitrile |
| [2-(benzyloxy)phenyl][(2-methoxyphenyl)amino]acetonitrile |
| STK555322 |
| bdbm50447010 |
| CHEMBL1509437 , |
| compound d24 [pmid: 24374347] |
| gtpl8834 |
| 2-[(2-methoxyphenyl)amino]-2-[2-(phenylmethoxy)phenyl]acetonitrile |
| 664972-15-0 |
| Q27076865 |
| Class | Description |
|---|---|
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| substituted aniline | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 15.8114 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 39.8107 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 50.1187 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| TDP1 protein | Homo sapiens (human) | Potency | 29.0929 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Smad3 | Homo sapiens (human) | Potency | 35.4813 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 17.7828 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| P53 | Homo sapiens (human) | Potency | 50.1187 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 39.8107 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
| geminin | Homo sapiens (human) | Potency | 0.5234 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 14.1254 | 0.0580 | 10.6949 | 26.6086 | AID602310 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Phosphatidylcholine:ceramide cholinephosphotransferase 2 | Homo sapiens (human) | IC50 (µMol) | 12.4000 | 1.0000 | 1.7857 | 4.0000 | AID1068359 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| sphingomyelin biosynthetic process | Phosphatidylcholine:ceramide cholinephosphotransferase 2 | Homo sapiens (human) |
| sphingolipid biosynthetic process | Phosphatidylcholine:ceramide cholinephosphotransferase 2 | Homo sapiens (human) |
| regulation of bone mineralization | Phosphatidylcholine:ceramide cholinephosphotransferase 2 | Homo sapiens (human) |
| ceramide phosphoethanolamine biosynthetic process | Phosphatidylcholine:ceramide cholinephosphotransferase 2 | Homo sapiens (human) |
| ceramide biosynthetic process | Phosphatidylcholine:ceramide cholinephosphotransferase 2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| ceramide phosphoethanolamine synthase activity | Phosphatidylcholine:ceramide cholinephosphotransferase 2 | Homo sapiens (human) |
| protein binding | Phosphatidylcholine:ceramide cholinephosphotransferase 2 | Homo sapiens (human) |
| kinase activity | Phosphatidylcholine:ceramide cholinephosphotransferase 2 | Homo sapiens (human) |
| sphingomyelin synthase activity | Phosphatidylcholine:ceramide cholinephosphotransferase 2 | Homo sapiens (human) |
| ceramide cholinephosphotransferase activity | Phosphatidylcholine:ceramide cholinephosphotransferase 2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| Golgi membrane | Phosphatidylcholine:ceramide cholinephosphotransferase 2 | Homo sapiens (human) |
| nucleoplasm | Phosphatidylcholine:ceramide cholinephosphotransferase 2 | Homo sapiens (human) |
| Golgi apparatus | Phosphatidylcholine:ceramide cholinephosphotransferase 2 | Homo sapiens (human) |
| plasma membrane | Phosphatidylcholine:ceramide cholinephosphotransferase 2 | Homo sapiens (human) |
| Golgi membrane | Phosphatidylcholine:ceramide cholinephosphotransferase 2 | Homo sapiens (human) |
| endoplasmic reticulum membrane | Phosphatidylcholine:ceramide cholinephosphotransferase 2 | Homo sapiens (human) |
| plasma membrane | Phosphatidylcholine:ceramide cholinephosphotransferase 2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1068359 | Inhibition of SMS2 (unknown origin) expressed in H5 insect cells using C6-NBD-Cer as substrate after 1 hr | 2014 | European journal of medicinal chemistry, Feb-12, Volume: 73 | Identification of small molecule sphingomyelin synthase inhibitors. |
| AID1068357 | Inhibition of sphingomyelin synthase in ICR mouse liver homogenates using C6-NBD-Cer as substrate after 2 hrs | 2014 | European journal of medicinal chemistry, Feb-12, Volume: 73 | Identification of small molecule sphingomyelin synthase inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.35) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||